Adolescent Health, Medicine and Therapeutics (May 2021)
Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review
Abstract
Catherine Copley-Merriman,1 Xiaoqin Yang,2 Melissa Juniper,1 Suvina Amin,3 Hyun Kyoo Yoo,4 Shuvayu S Sen2 1RTI Health Solutions, Research Triangle Park, NC, USA; 2Merck & Co., Inc., Kenilworth, NJ, USA; 3AstraZeneca, Gaithersburg, MD, USA; 4AstraZeneca, Cambridge, UKCorrespondence: Xiaoqin YangMerck & Co., Inc., Center for Observational and Real-World Evidence (CORE), 126 E. Lincoln Ave., RY33-216, Rahway, NJ, 07065, USATel +1 732 594 7587Email [email protected]: Neurofibromatosis type 1 (NF1) is an incurable genetic condition that frequently includes the development of plexiform neurofibromas (PNs) in patients. A systematic literature review was conducted to identify data on the natural history, disease burden, and treatment patterns among patients diagnosed with NF1 and PN, as well as to identify evidence gaps in these areas. MEDLINE and MEDLINE In-Process, Embase, and Cochrane Library Searches were searched using predefined terms. Potential references underwent two phases of screening by two independent researchers. A total of 39 references focusing on populations of patients with both NF1 and PN were included in this review. The wide range of PN-related complications creates a substantial quality-of-life (QOL) burden for patients, including pain, social functioning, physical function impact, stigma, and emotional distress. The severe burden of NF1 with PN on the QOL of patients demonstrates the high unmet need for an effective treatment option that can reduce tumor burden and improve QOL. The heterogeneity of measurement tools used to evaluate QOL and the gap in data evaluating the health economic burden of PN should be the focus of future research.Keywords: neurofibromatosis type 1, plexiform neurofibromas, quality of life, natural history, review
